Expression of human CD44v6 in non-small-cell lung cancer

P. Carbognani, L. Spaggiari, A. Romani, P. Solli, A. Corradi, Anna Maria Cantoni, P. G. Petronini, A. F. Borghetti, M. Rusca, P. Bobbio

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Introduction: The CD44 is a membrane glycoprotein that functions as lymph node homing receptor in lymphocyte activation and is involved in homo- and heterotypic cell adhesion. In several tumor cell lines the expression of splice variants (CD44v6 and CD44v7) are correlated with the metastatic potential and confer an advantage in the early steps of the metastatic cascade. In our study we examined 35 cases of non-small-cell lung cancers (NSCLC) in order to detect the presence of CD44v6 and to compare its expression with the histologic type, degree of differentiation, stage of the tumor and survival of the patients. Methods: CD44v6 expression in frozen tissue sections of 35 patients with NSCLC who underwent pneumonectomy or lobectomy was analyzed with the VFF-7 monoclonal antibody that detected the CD44v6 variant. The data on survival were analyzed by the actuarial method and compared by the log rank test. Results: The expression of CD44v6 occurred in all the 20 cases of epidermoid carcinomas tested and in 2 out of the 3 cases of undifferentiated large cell carcinoma and was absent in all the 12 adenocarcinomas. No relationship was found between the presence of this marker and the grading or the stage of the pathology. The 3-year survival rate was 73% for CD44v6-positive and 65% for CD44v6-negative cancer and the comparison was not statistically significant. Conclusion: These results suggest that in lung cancer the expression of CD44v6 is not a useful prognostic factor.

Original languageEnglish
Pages (from-to)403-408
Number of pages6
JournalEuropean Surgical Research
Volume30
Issue number6
Publication statusPublished - Nov 1998

Fingerprint

Non-Small Cell Lung Carcinoma
Lymphocyte Homing Receptors
Large Cell Carcinoma
Survival
Pneumonectomy
Membrane Glycoproteins
Frozen Sections
Lymphocyte Activation
Tumor Cell Line
Cell Adhesion
Squamous Cell Carcinoma
Lung Neoplasms
Neoplasms
Adenocarcinoma
Survival Rate
Monoclonal Antibodies
Pathology

Keywords

  • Cancer
  • CD44v6
  • Lung
  • Marker
  • Non-small-cell lung cancer

ASJC Scopus subject areas

  • Surgery

Cite this

Carbognani, P., Spaggiari, L., Romani, A., Solli, P., Corradi, A., Cantoni, A. M., ... Bobbio, P. (1998). Expression of human CD44v6 in non-small-cell lung cancer. European Surgical Research, 30(6), 403-408.

Expression of human CD44v6 in non-small-cell lung cancer. / Carbognani, P.; Spaggiari, L.; Romani, A.; Solli, P.; Corradi, A.; Cantoni, Anna Maria; Petronini, P. G.; Borghetti, A. F.; Rusca, M.; Bobbio, P.

In: European Surgical Research, Vol. 30, No. 6, 11.1998, p. 403-408.

Research output: Contribution to journalArticle

Carbognani, P, Spaggiari, L, Romani, A, Solli, P, Corradi, A, Cantoni, AM, Petronini, PG, Borghetti, AF, Rusca, M & Bobbio, P 1998, 'Expression of human CD44v6 in non-small-cell lung cancer', European Surgical Research, vol. 30, no. 6, pp. 403-408.
Carbognani P, Spaggiari L, Romani A, Solli P, Corradi A, Cantoni AM et al. Expression of human CD44v6 in non-small-cell lung cancer. European Surgical Research. 1998 Nov;30(6):403-408.
Carbognani, P. ; Spaggiari, L. ; Romani, A. ; Solli, P. ; Corradi, A. ; Cantoni, Anna Maria ; Petronini, P. G. ; Borghetti, A. F. ; Rusca, M. ; Bobbio, P. / Expression of human CD44v6 in non-small-cell lung cancer. In: European Surgical Research. 1998 ; Vol. 30, No. 6. pp. 403-408.
@article{c03235e575394ce38972c78ea6faf395,
title = "Expression of human CD44v6 in non-small-cell lung cancer",
abstract = "Introduction: The CD44 is a membrane glycoprotein that functions as lymph node homing receptor in lymphocyte activation and is involved in homo- and heterotypic cell adhesion. In several tumor cell lines the expression of splice variants (CD44v6 and CD44v7) are correlated with the metastatic potential and confer an advantage in the early steps of the metastatic cascade. In our study we examined 35 cases of non-small-cell lung cancers (NSCLC) in order to detect the presence of CD44v6 and to compare its expression with the histologic type, degree of differentiation, stage of the tumor and survival of the patients. Methods: CD44v6 expression in frozen tissue sections of 35 patients with NSCLC who underwent pneumonectomy or lobectomy was analyzed with the VFF-7 monoclonal antibody that detected the CD44v6 variant. The data on survival were analyzed by the actuarial method and compared by the log rank test. Results: The expression of CD44v6 occurred in all the 20 cases of epidermoid carcinomas tested and in 2 out of the 3 cases of undifferentiated large cell carcinoma and was absent in all the 12 adenocarcinomas. No relationship was found between the presence of this marker and the grading or the stage of the pathology. The 3-year survival rate was 73{\%} for CD44v6-positive and 65{\%} for CD44v6-negative cancer and the comparison was not statistically significant. Conclusion: These results suggest that in lung cancer the expression of CD44v6 is not a useful prognostic factor.",
keywords = "Cancer, CD44v6, Lung, Marker, Non-small-cell lung cancer",
author = "P. Carbognani and L. Spaggiari and A. Romani and P. Solli and A. Corradi and Cantoni, {Anna Maria} and Petronini, {P. G.} and Borghetti, {A. F.} and M. Rusca and P. Bobbio",
year = "1998",
month = "11",
language = "English",
volume = "30",
pages = "403--408",
journal = "European Surgical Research",
issn = "0014-312X",
publisher = "S. Karger AG",
number = "6",

}

TY - JOUR

T1 - Expression of human CD44v6 in non-small-cell lung cancer

AU - Carbognani, P.

AU - Spaggiari, L.

AU - Romani, A.

AU - Solli, P.

AU - Corradi, A.

AU - Cantoni, Anna Maria

AU - Petronini, P. G.

AU - Borghetti, A. F.

AU - Rusca, M.

AU - Bobbio, P.

PY - 1998/11

Y1 - 1998/11

N2 - Introduction: The CD44 is a membrane glycoprotein that functions as lymph node homing receptor in lymphocyte activation and is involved in homo- and heterotypic cell adhesion. In several tumor cell lines the expression of splice variants (CD44v6 and CD44v7) are correlated with the metastatic potential and confer an advantage in the early steps of the metastatic cascade. In our study we examined 35 cases of non-small-cell lung cancers (NSCLC) in order to detect the presence of CD44v6 and to compare its expression with the histologic type, degree of differentiation, stage of the tumor and survival of the patients. Methods: CD44v6 expression in frozen tissue sections of 35 patients with NSCLC who underwent pneumonectomy or lobectomy was analyzed with the VFF-7 monoclonal antibody that detected the CD44v6 variant. The data on survival were analyzed by the actuarial method and compared by the log rank test. Results: The expression of CD44v6 occurred in all the 20 cases of epidermoid carcinomas tested and in 2 out of the 3 cases of undifferentiated large cell carcinoma and was absent in all the 12 adenocarcinomas. No relationship was found between the presence of this marker and the grading or the stage of the pathology. The 3-year survival rate was 73% for CD44v6-positive and 65% for CD44v6-negative cancer and the comparison was not statistically significant. Conclusion: These results suggest that in lung cancer the expression of CD44v6 is not a useful prognostic factor.

AB - Introduction: The CD44 is a membrane glycoprotein that functions as lymph node homing receptor in lymphocyte activation and is involved in homo- and heterotypic cell adhesion. In several tumor cell lines the expression of splice variants (CD44v6 and CD44v7) are correlated with the metastatic potential and confer an advantage in the early steps of the metastatic cascade. In our study we examined 35 cases of non-small-cell lung cancers (NSCLC) in order to detect the presence of CD44v6 and to compare its expression with the histologic type, degree of differentiation, stage of the tumor and survival of the patients. Methods: CD44v6 expression in frozen tissue sections of 35 patients with NSCLC who underwent pneumonectomy or lobectomy was analyzed with the VFF-7 monoclonal antibody that detected the CD44v6 variant. The data on survival were analyzed by the actuarial method and compared by the log rank test. Results: The expression of CD44v6 occurred in all the 20 cases of epidermoid carcinomas tested and in 2 out of the 3 cases of undifferentiated large cell carcinoma and was absent in all the 12 adenocarcinomas. No relationship was found between the presence of this marker and the grading or the stage of the pathology. The 3-year survival rate was 73% for CD44v6-positive and 65% for CD44v6-negative cancer and the comparison was not statistically significant. Conclusion: These results suggest that in lung cancer the expression of CD44v6 is not a useful prognostic factor.

KW - Cancer

KW - CD44v6

KW - Lung

KW - Marker

KW - Non-small-cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=7844252588&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=7844252588&partnerID=8YFLogxK

M3 - Article

C2 - 9838232

AN - SCOPUS:7844252588

VL - 30

SP - 403

EP - 408

JO - European Surgical Research

JF - European Surgical Research

SN - 0014-312X

IS - 6

ER -